<code id='91D5066029'></code><style id='91D5066029'></style>
    • <acronym id='91D5066029'></acronym>
      <center id='91D5066029'><center id='91D5066029'><tfoot id='91D5066029'></tfoot></center><abbr id='91D5066029'><dir id='91D5066029'><tfoot id='91D5066029'></tfoot><noframes id='91D5066029'>

    • <optgroup id='91D5066029'><strike id='91D5066029'><sup id='91D5066029'></sup></strike><code id='91D5066029'></code></optgroup>
        1. <b id='91D5066029'><label id='91D5066029'><select id='91D5066029'><dt id='91D5066029'><span id='91D5066029'></span></dt></select></label></b><u id='91D5066029'></u>
          <i id='91D5066029'><strike id='91D5066029'><tt id='91D5066029'><pre id='91D5066029'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          focus

          author:knowledge    - browse:6973
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          hotspot